CORE--INVESTIGATIONAL DRUG

$0P30FY2002CANIH

University Of Wisconsin Madison, Madison WI

Investigators

Linked publications & trials

Paper 39638850 Paper 39604703 Paper 39580301 Paper 39530524 Paper 39527745 Paper 39516197 Paper 39484544 Paper 39481346 Paper 39474803 Paper 39462136 Paper 39452931 Paper 39444276 Paper 39443360 Paper 39432401 Paper 39414902 Paper 39408582 Paper 39407431 Paper 39402986 Paper 39399121 Paper 39386576 Paper 39386545 Paper 39379374 Paper 39374311 Paper 39364328 Paper 39358429 Paper 39345631 Paper 39335130 Paper 39312186 Paper 39301555 Paper 39298313 Paper 39292804 Paper 39288179 Paper 39284072 Paper 39271570 Paper 39257784 Paper 39246449 Paper 39208856 Paper 39199676 Paper 39167234 Paper 39166971 Paper 39128812 Paper 39119337 Paper 39109925 Paper 39106310 Paper 39104301 Paper 39080282 Paper 39072841 Paper 39058136 Paper 39038927 Paper 39036366 Paper 39026718 Paper 39020220 Paper 39011049 Paper 38984758 Paper 38975793 Paper 38965594 Paper 38958009 Paper 38948762 Paper 38940692 Paper 38922186 Paper 38915614 Paper 38912706 Paper 38895446 Paper 38895244 Paper 38882639 Paper 38853889 Paper 38851630 Paper 38832939 Paper 38826188 Paper 38813620 Paper 38810182 Paper 38798691 Paper 38771515 Paper 38768442 Paper 38759675 Paper 38753748 Paper 38747597 Paper 38736328 Paper 38718234 Paper 38702146 Paper 38699288 Paper 38696422 Paper 38687505 Paper 38672472 Paper 38669327 Paper 38666833 Paper 38639731 Paper 38617269 Paper 38598637 Paper 38597671 Paper 38590848 Paper 38588415 Paper 38580333 Paper 38576540 Paper 38554704 Paper 38531064 Paper 38526136 Paper 38521057 Paper 38518387 Paper 38515747

Abstract

The University of Wisconsin Hospital and Clinic's Investigational Drug Service (IDS) program provides clinical drug study design assistance, institutional protocol activation and study drug preparation and management to all UWCCC investigators conducting clinical drug research. IDS's core and supplemental services play a vital role in the success of the UWCCC's clinical drug research program. The comprehensive and flexible nature of the IDS program will continue to be of great importance to UWCCC as programs such as chemoprevention, experimental therapeutics, and gene therapy grow in size and complexity.

View original record on NIH RePORTER →